Rat Osteoprotegerin,OPG ELISA KIT

Code CSB-E07404r
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

The rat OPG ELISA kit is a solid-phase immunoassay specially designed to quantitatively measure rat OPG in serum, plasma, or tissue homogenates. It is based on the Sandwich-ELISA mechanism. OPG in the sample is bound to the capture antibody immobilized on the 96-well strip plate and then sandwiched with the biotinylated OPG antibody. After the addition of HRP-avidin and TMB substrate, the solution in the wells turns blue. The color reaction is stopped by adding the stop solution into the wells, and the color changes from blue to yellow. The color intensity is positively proportional to the OPG bound in the initial step. The OPG concentration can be calculated according to the standard curve. This kit is tested with high sensitivity and strong specificity.

OPG, also called TNFRSF11B, is a secreted glycoprotein central to bone turnover via its role as a decoy receptor for the RANKL. The OPG/RANK/RANKL network is involved in bone remodeling and modulates the differentiation and activation of osteoclasts and hence the critical balance between bone formation and bone resorption. OPG-RANKL inhibits RANKL/RANK interaction, thus blocking osteoclastogenesis. OPG has traditionally been linked to a number of bone-related diseases. In vitro studies indicate that OPG is expressed in cells involved in atheroma plaque development and progression, such as arterial smooth muscle cells and pulmonary artery smooth muscle cells. It also seems to play an important role on cell survival through its interaction with TRAIL.

Target Name tumor necrosis factor receptor superfamily, member 11b
Alternative Names Tnfrsf11b ELISA Kit; Opg ELISA Kit; Tumor necrosis factor receptor superfamily member 11B ELISA Kit; Osteoprotegerin ELISA Kit
Abbreviation TNFRSF11B
Uniprot No. O08727
Species Rattus norvegicus (Rat)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.78 ng/ml - 50 ng/ml
Sensitivity 0.195 ng/ml
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision  
Linearity  
Recovery  
Typical Data  
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Gene References into Functions
  1. Adipose-derived stem cell-released osteoprotegerin protects cardiomyocytes from reactive oxygen species-induced cell death. PMID: 28931423
  2. An upregulation of OPG was observed in the ovariectomized rats with streptozotocin-induced type 1 diabetes mellitus plus daily Zn supplementation group compared with the nonsupplemented and control groups. PMID: 28473060
  3. the canonical Wnt pathway inhibitor DKK1 blocked the osteogenesis effect and rescued the ratio of RANKL/OPG in periodontal ligament stem cells under force treatment for 1h. PMID: 27154288
  4. FGF21 inhibited VSMCs calcification via OPG/RANKL system, and through P38 andPI3K/AKT pathways. PMID: 28774557
  5. this study shows that flavonoids of Astragalus exert protective effects against adjuvant arthritis by regulating OPG/RANKL/NF-kappaB pathway PMID: 28092862
  6. In addition, curcumin upregulated the mRNA expression levels of transcription factors that favor osteoblast differentiation and increased the ratio of OPG to RANKL. PMID: 26677102
  7. The ratio of RANKL to OPG was very low during most of the arterial calcification period, which allowed for OPG to completely inhibit RANKL-induced osteoclast-like cell differentiation and to promote calcification. PMID: 26489619
  8. RANKL and OPG expressions were not changed by chronic exposure to fluoride in the drinking water during the studied periods; on the other hand, TRAP expression was changed (at 7 days) by chronic exposure to fluoride PMID: 22878484
  9. Lowering the serum homocysteine level by a simultaneous supplementation with N-acetylcysteine improved OPG and FOXO1 expression and partially antagonized RANKL and proresorptive cytokine synthesis in the bone milieu PMID: 23500899
  10. High-dose diosgenin treatment up-regulated expression of OPG significantly in tibia from OVX rats compared to control. PMID: 25257532
  11. Data indicate that the highest expression level of osteoprotegerin(OPG) was observed in jump (J) group. PMID: 25200151
  12. Cadmium could enhance receptor-activated nuclear factor kappa B ligand expression (RANKL) and inhibit osteoprotegerin (OPG) expression. PMID: 23954550
  13. RANKL and OPG expression promotes osteoclast development and enhances its function under the condition of estrogen deficiency PMID: 24321069
  14. Pulsed electromagnetic field can prevent ovariectomy-induced bone loss through regulating the expression of RANKL and OPG. PMID: 22948539
  15. Bisphosphonate in bone cement affects bone turnover by stimulating an increase in osteoprotegerin and a decrease in RANKL in the bone microenvironment. PMID: 23404413
  16. The concentration of sRANKL in gingival crevicular fluid increased significatly, then decreased sharply after orthodontic retention and bone remodeling. PMID: 22353912
  17. Epimedium extract can prevent glucocorticoid-induced femoral head necrosis probably by antagonizing glucocorticiod-induced abnormal expressions of OPG and RANKL mRNA. PMID: 22027774
  18. Ultrasound stimulation might be useful to protect against root resorption and accelerate its repair by regulating the expressions of OPG and RANKL. PMID: 21602131
  19. Ovariectomy caused a significant decrease in OPG gene expression in the tibia and aorta PMID: 21519319
  20. The temporospatial expression patterns of osteoprotegerin and RANKL suggest that osteoblasts and the lineage cell network orchestrates bone remodelling during distraction osteogenesis. PMID: 18476557
  21. except for the period of time in tooth eruption, where osteoclast formation is needed to form an eruption pathway, secretion of OPG (osteoprotegerin) prevents resorption of alveolar bone and subsequent disruption of the periodontal ligament PMID: 11839361
  22. reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis PMID: 12368214
  23. Detection of osteoprotegerin mRNA and protein in bone cells. PMID: 15704000
  24. Regulation of OPG production by the dental follicle likely affects the alveolar bone resorption needed for tooth eruption. PMID: 16283633
  25. RANK expression stimulates the activation and differentiation of osteoclast-like cells via low level laser irradiation in osteoclast precursor cells. PMID: 16568210
  26. Cytokine-induced production of OPG may protect beta cells from further damage, an effect mediated through inhibition of p38 map kinase phosphorylation. PMID: 17443309
  27. Results describe the effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. PMID: 17476578
  28. Systemic delivery of osteoprotegerin inhibits alveolar bone resorption in experimental periodontitis, suggesting that RANKL inhibition may represent an important therapeutic strategy for the prevention of progressive alveolar bone loss. PMID: 17608585
  29. abnormal elevation of the OPG/tumor necrosis factor (ligand) superfamily member 10 ratio in the vessel wall characterizes the early onset of diabetes mellitus PMID: 17627577
  30. Data demonstrate that hyperprolactinemia can act directly on bone to stimulate bone turnover, and that prolactin enhances bone resorption in part by increasing RANKL and decreasing osteoprotegerin expression by osteoblasts. PMID: 18166509
  31. OPG/RANK/RANKL axis may be involved in cardiac remodeling in immuno-inflammatory myocardial diseases and progression of chronic HF and thus may represent targets for intervention in this disorder. PMID: 18417124
  32. Prolactin decreased osteoprotegerin mrna in cultured osteoblasts. PMID: 18432284
  33. demonstrate an imbalance of RANKL/OPG expression associated with diabetes that may contribute to the delay of fracture repair during the course of diabetes PMID: 18592139
  34. HLA-B27 transgenic rats show a reduced bone mass, and suggest an involvement of the RANKL/OPG system in the mechanism of bone loss in this disease PMID: 19040304
  35. OPG is a positive regulator of microvessel formation, while RANKL is an angiogenic inhibitor due to effects on regulation of endothelial cell proliferation, apoptosis, and signaling. PMID: 19105036
  36. low bone turnover after 1 yr of OPG overexpression in rats was associated with increased vertebral bone mass and proportional increases in bone strength, with no evidence for deleterious effects on vertebral material properties. PMID: 19257823
  37. Different values of traction force cause a variation of the RANKL/OPG ratio through the expression of RANKL protein, modulating the activities of bone remodeling in the subchondral bone of condyle. PMID: 19537860
  38. Orchiectomized rats exhibited increased RANKL protein in bone marrow plasma and in bone marrow cells, with no changes in serum RANKL. PMID: 19539794

Show More

Hide All

Subcellular Location Secreted.
Database Links

KEGG: rno:25341

STRING: 10116.ENSRNOP00000011344

UniGene: Rn.202973

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1